Literature DB >> 29138517

Hypertension: Device therapy for uncontrolled hypertension: new approaches to an old problem.

Peter J Blankestijn1, Michiel L Bots1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29138517     DOI： 10.1038/nrneph.2017.150

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial.

Authors:  Rosa L de Jager; Esther de Beus; Martine M A Beeftink; Margreet F Sanders; Evert-Jan Vonken; Michiel Voskuil; Erik M van Maarseveen; Michiel L Bots; Peter J Blankestijn
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

2.  Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.

Authors:  Clara K Chow; Jay Thakkar; Alex Bennett; Graham Hillis; Michael Burke; Tim Usherwood; Kha Vo; Kris Rogers; Emily Atkins; Ruth Webster; Michael Chou; Hakim-Moulay Dehbi; Abdul Salam; Anushka Patel; Bruce Neal; David Peiris; Henry Krum; John Chalmers; Mark Nelson; Christopher M Reid; Mark Woodward; Sarah Hilmer; Simon Thom; Anthony Rodgers
Journal:  Lancet       Date:  2017-02-10       Impact factor: 79.321

3.  Risk Factors for Nonadherence to Antihypertensive Treatment.

Authors:  Pankaj Gupta; Prashanth Patel; Branislav Štrauch; Florence Y Lai; Artur Akbarov; Věra Marešová; Christobelle M J White; Ondřej Petrák; Gaurav S Gulsin; Veena Patel; Ján Rosa; Richard Cole; Tomáš Zelinka; Robert Holaj; Angela Kinnell; Paul R Smith; John R Thompson; Iain Squire; Jiří Widimský; Nilesh J Samani; Bryan Williams; Maciej Tomaszewski
Journal:  Hypertension       Date:  2017-05-01       Impact factor: 10.190

4.  Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study.

Authors:  Wilko Spiering; Bryan Williams; Jan Van der Heyden; Monique van Kleef; Rob Lo; Jorie Versmissen; Adriaan Moelker; Abraham Kroon; Hannes Reuter; Gary Ansel; Gregg W Stone; Mark Bates
Journal:  Lancet       Date:  2017-09-01       Impact factor: 79.321

5.  Catheter-based renal denervation as therapy for chronic severe kidney-related pain.

Authors:  Rosa L de Jager; Niek F Casteleijn; Esther de Beus; Michiel L Bots; Evert-Jan E Vonken; Ron T Gansevoort; Peter J Blankestijn
Journal:  Nephrol Dial Transplant       Date:  2018-04-01       Impact factor: 5.992

Review 6.  Sympathetic activation secondary to chronic kidney disease: therapeutic target for renal denervation?

Authors:  Esther de Beus; Rosa de Jager; Jaap A Joles; Guido Grassi; Peter J Blankestijn
Journal:  J Hypertens       Date:  2014-09       Impact factor: 4.844

7.  Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study.

Authors:  Eva E Vink; Roel Goldschmeding; Aryan Vink; Callista Weggemans; Ronald L A W Bleijs; Peter J Blankestijn
Journal:  Nephrol Dial Transplant       Date:  2014-05-29       Impact factor: 5.992

8.  Renal denervation in hypertensive patients not on blood pressure lowering drugs.

Authors:  Rosa L De Jager; Margreet F Sanders; Michiel L Bots; Melvin D Lobo; Sebastian Ewen; Martine M A Beeftink; Michael Böhm; Joost Daemen; Oliver Dörr; Dagmara Hering; Felix Mahfoud; Holger Nef; Christian Ott; Manish Saxena; Roland E Schmieder; Markus P Schlaich; Wilko Spiering; Pim A L Tonino; Willemien L Verloop; Eva E Vink; Evert-Jan Vonken; Michiel Voskuil; Stephen G Worthley; Peter J Blankestijn
Journal:  Clin Res Cardiol       Date:  2016-04-22       Impact factor: 5.460

9.  Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet       Date:  2017-09-16       Impact factor: 79.321

10.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.

Authors:  Raymond R Townsend; Felix Mahfoud; David E Kandzari; Kazuomi Kario; Stuart Pocock; Michael A Weber; Sebastian Ewen; Konstantinos Tsioufis; Dimitrios Tousoulis; Andrew S P Sharp; Anthony F Watkinson; Roland E Schmieder; Axel Schmid; James W Choi; Cara East; Anthony Walton; Ingrid Hopper; Debbie L Cohen; Robert Wilensky; David P Lee; Adrian Ma; Chandan M Devireddy; Janice P Lea; Philipp C Lurz; Karl Fengler; Justin Davies; Neil Chapman; Sidney A Cohen; Vanessa DeBruin; Martin Fahy; Denise E Jones; Martin Rothman; Michael Böhm
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.